{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:05Z","timestamp":1784945825660,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary angle closure disease (PACD) is a type of glaucoma in which the intraocular pressure (IOP) is increased because of the blockage of the anterior chamber angle. Medications contraindicated for patients with PACD, such as anticholinergics, cause mydriasis, and can elevate IOP. However, anticholinergics are currently contraindicated only for primary angle closure glaucoma (PACG) in Japanese package inserts. In this study, we investigated the prescription status of medications contraindicated for PACD, such as anticholinergics, in patients with PACD scheduled for eye surgeries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-three Japanese patients diagnosed with PACD at Kobe City Eye Hospital, Japan, and scheduled hospitalization for eye surgeries between December 2017 and July 2018, were included. Data, including sex, age, diagnosis, IOP, anterior chamber depth, and patients\u2019 regular medications prior to hospitalization, were collected for each patient from the electronic medical records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of patients with chronic primary angle closure (CPAC) and acute primary angle closure (APAC) was 35 (81.4%) and 8 (18.6%), respectively. Among all the 43 patients with PACD, 8 (18.6%) received 15 medications that are potentially contraindicated for PACD by non-ophthalmologist. According to medication categories, benzodiazepine hypnotics were the most commonly prescribed. Among the 8 patients with APAC, 2 (25.0%) had routinely received medications contraindicated for PACD. The median number of all kinds of prescriptions on the day of hospitalization was significantly higher for patients who received medications contraindicated for PACD than for those who did not receive them (<jats:italic>p<\/jats:italic>\u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>About 20% of patients with PACD received medications potentially contraindicated for PACD, such as anticholinergics. Attention should be paid to patients prescribed multiple drugs for adverse events, such as increase in intraocular pressure.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-021-00196-w","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T14:54:51Z","timestamp":1620053691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting"],"prefix":"10.1186","volume":"7","author":[{"given":"Fumiaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shibatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ikesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yoshimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"196_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/bjo.86.2.238","volume":"86","author":"PJ Foster","year":"2002","unstructured":"Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238\u201342.","journal-title":"Br J Ophthalmol"},{"key":"196_CR2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology."},{"key":"196_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2011.12.038","volume":"119","author":"S Sawaguchi","year":"2012","unstructured":"Sawaguchi S, Sakai H, Iwase A, Yamamoto T, Abe H, Tomita G, et al. Prevalence of primary angle closure and primary angle-closure glaucoma in a southwestern rural population of Japan. Ophthalmology. 2012;119:1134\u201342.","journal-title":"Ophthalmology."},{"key":"196_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1447-0594.2012.00868.x","volume":"12","author":"T Kojima","year":"2012","unstructured":"Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761\u20132.","journal-title":"Geriatr Gerontol Int"},{"key":"196_CR5","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.1969.03150240109015","volume":"207","author":"WM Grant","year":"1969","unstructured":"Grant WM. Ocular complications of drugs. JAMA. 1969;207:2089\u201391.","journal-title":"JAMA."},{"key":"196_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2165\/00002018-200326110-00002","volume":"26","author":"RC Tripathi","year":"2003","unstructured":"Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26:749\u201367.","journal-title":"Drug Saf"},{"key":"196_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICU.0b013e32808738d5","volume":"18","author":"Y Lachkar","year":"2007","unstructured":"Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007;18:129\u201333.","journal-title":"Curr Opin Ophthalmol"},{"key":"196_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.amjmed.2010.08.011","volume":"124","author":"MR Razeghinejad","year":"2011","unstructured":"Razeghinejad MR, Myers JS, Katz LJ. Iatrogenic glaucoma secondary to medications. Am J Med. 2011;124:20\u20135.","journal-title":"Am J Med"},{"key":"196_CR9","first-page":"139","volume":"18","author":"JS Lai","year":"2012","unstructured":"Lai JS, Gangwani RA. Medication-induced acute angle closure attack. Hong Kong Med J. 2012;18:139\u201345.","journal-title":"Hong Kong Med J"},{"key":"196_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5694\/j.1326-5377.1986.tb113739.x","volume":"145","author":"AM Brooks","year":"1986","unstructured":"Brooks AM, West RH, Gillies WE. The risk of precipitating acute angle-closure glaucoma with the clinical use of mydriatic agents. Med J Aust. 1986;145:34\u20136.","journal-title":"Med J Aust"},{"key":"196_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1046\/j.1464-410x.1998.00403.x","volume":"81","author":"VC Sung","year":"1998","unstructured":"Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol. 1998;81:634\u20135.","journal-title":"Br J Urol"},{"key":"196_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0140-6736(84)91242-X","volume":"2","author":"GE Packe","year":"1984","unstructured":"Packe GE, Cayton RM, Mashhoudi N. Nebulised ipratropium bromide and salbutamol causing closed-angle glaucoma. Lancet. 1984;2:691.","journal-title":"Lancet."},{"key":"196_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/bmj.1.5800.605","volume":"1","author":"Z Friedman","year":"1972","unstructured":"Friedman Z, Neumann E. Benzhexol-induced blindness in Parkinson\u2019s disease. Br Med J. 1972;1:605.","journal-title":"Br Med J"},{"key":"196_CR14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s10792-017-0628-x","volume":"38","author":"SD Nicoar\u0103","year":"2018","unstructured":"Nicoar\u0103 SD, Damian I. Bilateral simultaneous acute angle closure attack triggered by an over-the-counter flu medication. Int Ophthalmol. 2018;38:1775\u20138.","journal-title":"Int Ophthalmol"},{"key":"196_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ggi.12591","volume":"16","author":"T Kojima","year":"2016","unstructured":"Kojima T, Shimada K, Terada A, Nishizawa K, Matsumoto K, Yoshimatsu Y, et al. Association between polypharmacy and multiple uses of medical facilities in nursing home residents. Geriatr Gerontol Int. 2016;16:770\u20131.","journal-title":"Geriatr Gerontol Int"},{"key":"196_CR16","doi-asserted-by":"publisher","first-page":"e016358","DOI":"10.1136\/bmjopen-2017-016358","volume":"7","author":"NN Dhalwani","year":"2017","unstructured":"Dhalwani NN, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7:e016358.","journal-title":"BMJ Open"},{"key":"196_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanct\u00f4t KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169.","journal-title":"BMJ."},{"key":"196_CR18","doi-asserted-by":"crossref","unstructured":"The 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674\u201394.","DOI":"10.1111\/jgs.15767"},{"key":"196_CR19","unstructured":"Belsomra\u2122 (suvorexant) tablets [package inserts]. MSD K.K. Tokyo, Japan; January 2020. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170050_1190023F1024_1_12. Accessed 11 July 2020."},{"key":"196_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2490-13-45","volume":"13","author":"V Khullar","year":"2013","unstructured":"Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian phase 3 trial. BMC Urol. 2013;13:45.","journal-title":"BMC Urol"},{"key":"196_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73:783\u201390.","journal-title":"Eur Urol"},{"key":"196_CR22","unstructured":"Betanis\u2122 (mirabegron) tablets [package inserts]. Astellas K.K. Tokyo, Japan; July 2019. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/800126_2590014F1021_1_12. Accessed 11 July 2020."}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-021-00196-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T15:14:04Z","timestamp":1620054844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-021-00196-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["196"],"URL":"https:\/\/doi.org\/10.1186\/s40780-021-00196-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Ethics Committee of the Kobe City Medical Center General Hospital; the Committee waived the need for patients\u2019 consent (approval no. ezn190101).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}